Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads

Inclusion Criteria: * Be scheduled for a transarterial chemoembolization using drug eluting beads for treatment of hepatocellular carcinoma * Be medically stable * If a female of child-bearing potential, must have a negative pregnancy test * Have signed Informed Consent to participate in the study Exclusion Criteria: * Females who are pregnant or nursing * Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable; for example: * Patients on life support or in a critical care unit * Patients with unstable occlusive disease (eg, crescendo angina) * Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia * Patients with uncontrolled congestive heart failure (New York Heart Association \[NYHA\] class IV) * Patients with recent cerebral hemorrhage * Patients with clinically significant and unstable renal disease (eg, transplant recipients in rejection) * Patients who have undergone surgery within 24 hours prior to the study sonographic examination * Patients with known hypersensitivity to perflutren * Patients who have received any contrast medium (x-ray, MRI, computed tomography \[CT\], or ultrasound \[US\]) in the 24 hours prior to the research US exam * Patients with cardiac shunts * Patients with congenital heart defects * Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli * Patients with respiratory distress syndrome